NCT02704156View on ClinicalTrials.gov

SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Pancreatic Cancer
Interventions
DEVICE

Cyberknife plus Pembrolizumab and Trametinib

Radiation therapy plus drug

DEVICE

Cyberknife plus Gemcitabine

Radiation therapy plus drug

Trial Locations (1)

200433

Changhai hospital, Shanghai

All Listed Sponsors
lead

Changhai Hospital

OTHER

NCT02704156 - SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer | Biotech Hunter | Biotech Hunter